The massive preparation of clinical trial data for broad secondary use represents a significant challenge and opportunity for the biopharma industry.  Come see how Novartis' data42 program has built out its R&D-wide data & analytics platform to enable scientists, clinicians, data scientists, and engineers to bring forth innovations to advance science and medicine.  This particular session will focus on the applications and uses of the platform via a case study review.

The data integration and fairification program in Boehringer Ingelheim R+D supports many of the accelerations needed for our pipeline. Learn about the possibilities to drive advanced data analysis and save experiments by making data accessible and interoperable between disciplines. Understand how the data culture also fosters better mutual understanding and communication between the disciplines. See, which opportunities lie in the better data access and interoperability in terms of troubleshooting, decision making, risk assessment and developability of biologicals development. Last but not least, data integration serves as an enabler for acceleration to the patient and market.

Data leaders should be front and center to execute digital health strategy. In many cases, data strategy does not deserve sufficient priority and is substantially underinvested. This presentation demonstrates how to position data strategy as a top priority, ensure sufficient resource allocation to execute your data roadmap, celebrate data-driven successes to fuel a sustainable digital transformation.

Cell and Gene Therapy (CGT) and Advanced Therapy Medicinal Products (ATMPs) have the potential to transform medicine. Today, delivering these medicines are costly, complex, and time-consuming. Digitisation and automation of the manufacturing and supply chain processes end-to-end focused on the patient journey with an upfront integrated approach is essential for building a scalable CGT platform. Here we present our design and architecture for a robust end-to-end CGT digital ecosystem.

Knowledge Management (KM) can deliver processes and tools to standardize and structure the flow of information. While it is mandatory as part of Pharmaceutical Quality by Design, even large pharma struggles with efficient implementations. This talk will present learnings from a 7-year KM strategy that has been largely successful; including how to build trust early on through cool technology, balance technology and change (OCM), ensure focus through start-up mentality, improve velocity with R&D IT & digital, focus on scale-out for impact, and other topics.

Advanced machine learning approaches enable the predictive models that support drug discovery to also benefit from unconventional data sources. A first example is the use of microscopy images for systematic de-risking. A second is the leveraging of multiparty data through privacy-preserving and federated learning. In MELLODDY, ten pharma all realized aggregated model improvements by training on 2.6B+ confidential experimental activity datapoints, documenting 21M+ physical molecules and 40K+ discovery-relevant assays.

This talk will explore how Genomics England is collaborating to help research partners maximize discovery in our research environment and enable our shared vision for the future to enable deeper genomic research through multimodal data, bringing genomic healthcare to all who need it.

Organizations are investing and making data a strategic priority for organization growth, productivity, and innovation. In this session we will share how organizations measure data maturity in a standard way. The recent Boston Consulting Group’s (BCG) Data Capability Maturity (DACAMA) survey gives a detailed overview of more than 1,100 companies who participated worldwide, representing nine major industry clusters. These survey results help to validate the prioritization and funding of data initiatives in the organization transformation journey. We will share a use case on how one of the client organizations used these results to prioritize their data capabilities that add value to their organization growth.